VAISHALI Stock Overview
Engages in the pharmaceutical business in India and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 1/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Vaishali Pharma Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹18.00 |
| 52 Week High | ₹24.91 |
| 52 Week Low | ₹12.49 |
| Beta | 0.42 |
| 1 Month Change | 1.69% |
| 3 Month Change | -4.84% |
| 1 Year Change | -3.07% |
| 3 Year Change | 371.82% |
| 5 Year Change | 367.53% |
| Change since IPO | 363.77% |
Recent News & Updates
Investors Give Vaishali Pharma Limited (NSE:VAISHALI) Shares A 33% Hiding
Nov 15
A Piece Of The Puzzle Missing From Vaishali Pharma Limited's (NSE:VAISHALI) 27% Share Price Climb
Sep 13Recent updates
Investors Give Vaishali Pharma Limited (NSE:VAISHALI) Shares A 33% Hiding
Nov 15A Piece Of The Puzzle Missing From Vaishali Pharma Limited's (NSE:VAISHALI) 27% Share Price Climb
Sep 13The Market Lifts Vaishali Pharma Limited (NSE:VAISHALI) Shares 26% But It Can Do More
Jul 05Here's Why Vaishali Pharma (NSE:VAISHALI) Has Caught The Eye Of Investors
Jan 17Vaishali Pharma Limited's (NSE:VAISHALI) Shares Leap 30% Yet They're Still Not Telling The Full Story
Dec 18Is Vaishali Pharma (NSE:VAISHALI) A Risky Investment?
Dec 11We Ran A Stock Scan For Earnings Growth And Vaishali Pharma (NSE:VAISHALI) Passed With Ease
Oct 04With EPS Growth And More, Vaishali Pharma (NSE:VAISHALI) Makes An Interesting Case
Feb 04Vaishali Pharma (NSE:VAISHALI) Seems To Use Debt Quite Sensibly
Dec 10We Ran A Stock Scan For Earnings Growth And Vaishali Pharma (NSE:VAISHALI) Passed With Ease
Aug 20Should You Be Adding Vaishali Pharma (NSE:VAISHALI) To Your Watchlist Today?
May 19These 4 Measures Indicate That Vaishali Pharma (NSE:VAISHALI) Is Using Debt Reasonably Well
Feb 10A Look At The Intrinsic Value Of Vaishali Pharma Limited (NSE:VAISHALI)
Aug 17A Look At The Fair Value Of Vaishali Pharma Limited (NSE:VAISHALI)
May 17Are Vaishali Pharma Limited's (NSE:VAISHALI) Fundamentals Good Enough to Warrant Buying Given The Stock's Recent Weakness?
Mar 17Calculating The Fair Value Of Vaishali Pharma Limited (NSE:VAISHALI)
Feb 15Does Vaishali Pharma (NSE:VAISHALI) Have A Healthy Balance Sheet?
Jan 19
Are Vaishali Pharma Limited's (NSE:VAISHALI) Mixed Financials Driving The Negative Sentiment?
Nov 23Shareholder Returns
| VAISHALI | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | 2.0% | 3.1% | 0.5% |
| 1Y | -3.1% | 36.2% | 17.4% |
Return vs Industry: VAISHALI underperformed the Indian Pharmaceuticals industry which returned 36.2% over the past year.
Return vs Market: VAISHALI underperformed the Indian Market which returned 17.4% over the past year.
Price Volatility
| VAISHALI volatility | |
|---|---|
| VAISHALI Average Weekly Movement | 8.9% |
| Pharmaceuticals Industry Average Movement | 5.9% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in IN Market | 9.0% |
| 10% least volatile stocks in IN Market | 4.1% |
Stable Share Price: VAISHALI's share price has been volatile over the past 3 months compared to the Indian market.
Volatility Over Time: VAISHALI's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of Indian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1989 | 27 | Hemanth Pathak | www.vaishalipharma.com |
Vaishali Pharma Limited engages in the pharmaceutical business in India and internationally. It offers active pharmaceutical ingredients (APIs), including antibiotics, anti-ulcer, anti-inflammatory/analgesic/anti-pyretic, anti-malarial, cardiac, anti-diabetic, anti-cold/anti-allergic, anti-diarrheal/anti-protozoal/anti-parasitic, anti-viral, anti-epileptic, anti-asthmatic, anti-fungal, anti-platelet agent, skeletal muscle relaxant, and anti-helmintic drugs, as well as excipients, topical steroids, corticosteroids, and enzymes. The company also provides formulation products, such as antibiotics/antibacterial, anti platelet, laxative, anti-ulcer/enzyme, anti-asthmatic, anti malarial, anti-cold/anti-allergic/anti-viral, anti-psychotic, cardiac, anti-diabetic, anti-inflamatory/ananlgesic/anti-pyretic, topical steroids/corticosteroids, anti-fungal, vitamins, and other formulations.
Vaishali Pharma Limited Fundamentals Summary
| VAISHALI fundamental statistics | |
|---|---|
| Market cap | ₹2.18b |
| Earnings (TTM) | ₹10.97m |
| Revenue (TTM) | ₹991.57m |
198.5x
P/E Ratio2.2x
P/S RatioIs VAISHALI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VAISHALI income statement (TTM) | |
|---|---|
| Revenue | ₹991.57m |
| Cost of Revenue | ₹875.59m |
| Gross Profit | ₹115.98m |
| Other Expenses | ₹105.02m |
| Earnings | ₹10.97m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.091 |
| Gross Margin | 11.70% |
| Net Profit Margin | 1.11% |
| Debt/Equity Ratio | 18.2% |
How did VAISHALI perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/02 04:11 |
| End of Day Share Price | 2025/01/02 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Vaishali Pharma Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|